Servier

Servier is a privately owned pharmaceutical company with a long-standing commitment to research and development. Worldwide, approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation. Servier is proud to support the Australian Diabetes Society through the Barry Young Research Grants.

Servier Australia’s commercial interests include Diabetes (Nesina – alogliptin & Nesina Met – alogliptin and metformin HCI) Cardiovascular Disease (Coveram – perindopril and amlodipine, Coversyl – perindopril arginine,  Coralan – ivabradine), Neuroscience, (Valdoxan – agomelatine and  Latuda – lurasidone), and oncology Lonsurf (trifluridine/tipiracil).

Find out more about Servier at http://www.servier.com.au/